WuXi AppTec expands site in California for pharmaceutical R&D services13 Dec 2018
Expanded facility will establish a center of excellence in screening, discovery biology, pharmacology, and small molecule process R&D including Phase I GMP manufacturing.
WuXi AppTec has announced the expansion of its facilities in San Diego, California.
WuXi AppTec's newly expanded facility will establish a center of excellence in screening, discovery biology, pharmacology, and small molecule process R&D including Phase I GMP manufacturing. The expansion will provide key elements of WuXi's small molecule capability and technology platform under one roof, further enhancing services to North American pharmaceutical and biotech industries. WuXi will also add extensively from the local talent base, further contributing to regional economic growth.
"Having a leading global organization like WuXi significantly invest in San Diego highlights the value of international partnerships, the county's place on the Pacific Rim and our region's long-standing support of the life sciences community," said San Diego County Supervisor Ron Roberts. "I especially applaud the company's vision that 'every drug can be made, and every disease can be treated."
"The San Diego life science community continues to thrive with the commitments and investments made by leading international powerhouses like WuXi AppTec," said Joe Panetta, president and CEO of Biocom. "Their latest facility expansion in San Diego is a testament to the deep relationships they have built with the local biotech community. Biocom applauds the positive impact they've had on the region's economic growth and innovative healthcare products for our patients."
"This expansion will enable us to better serve our U.S. and global customers, and contribute to the growth and success of the dynamic San Diego biotech ecosystem," said Dr. Ge Li, Chairman and CEO of WuXi AppTec. "Together with our ecosystem partners, we will continue to strengthen WuXi's capability and technology enabling platform to expedite the discovery and development of new medicines for patients worldwide, and for a future where every drug can be made and every disease can be treated."
Allergan to establish R&D presence in Cambridge, Massachusetts
10 Jan 2019
The new, strategic presence will allow the company to more easily interact and engage with venture firms and start ups in the area.Read more
Expedeon signs supply and license agreement for is Lightning-Link technology
9 Jan 2019
The technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results.Read more
Cambrex expands analytical capabilities
12 Dec 2018
The $1 million investment will assist in getting new products to commercial launch faster.Read more
MIT engineers repurpose wasp venom as an antibiotic drug
9 Dec 2018
Altered peptides from a South American wasp’s venom can kill bacteria but are nontoxic to human cells.Read more
Spanish CDMO working ahead of EU serialisation deadline
6 Dec 2018
Company now able to serialise commercial batches manufactured by them for clients; it can also offer standalone serialisation services as an outsourcing partner.Read more
Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases
5 Dec 2018
The financing will power the global commercial launch of the company's Fluidity One system.Read more
OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD
4 Dec 2018
The new treatment will leverage OnDosis’ proprietary technology, which integrates oral drugs in form of micro units and individualised dosing, in a handheld device.Read more
NIH to evaluate effectiveness of male contraceptive skin gel
28 Nov 2018
The gel formulation includes the progestin compound segesterone acetate, in combination with testosterone, and is applied to the back and shoulders and absorbed through the skin.Read more
QPS expands US-based Phase I clinical trial capabilities
27 Nov 2018
Expansion supports the growing needs of the company's pharmaceutical, biotechnology and CRO partners.Read more
Grant winners to investigate continuous manufacturing for gene therapies
26 Nov 2018
Cobra Biologics, Pall, and the Cell and Gene Therapy Catapult share £1.5 million grant from the UK's innovation agency.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation